Dataset Information

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.

ABSTRACT:

Background & objective

Although data on the effects of liraglutide and semaglutide in patients with diabetes have been reviewed, their therapeutic outcomes in obese/overweight individuals without diabetes have not been summarized. We conducted a systematic review to evaluate their effects on the latter population.

Methods

We searched the PubMed, EMBASE, Cochrane, CNKI, and Wanfang databases. Studies regarding obese/overweight adults without diabetes treated with liraglutide/semaglutide compared with other active agents or placebos were accessed. The primary outcomes were the proportions of adults with at least 5% and 10% weight reduction. The secondary outcomes included metabolic indicators and adverse events.

Results

Eighteen studies with 10,938 obese/overweight adults without diabetes were included. When stratified by the categories of at least 5% and 10% weight loss, the pooled data showed medians 27.7% and 10.3% of control groups versus 65.3% and 30.7% of liraglutide 3 mg once daily, respectively; whereas medians 47.6% and 20.4% of control groups vs 86.6% and 75.3% of semaglutide 2.4 mg once weekly were found in the two categories, respectively. Both agents either improved or had no impact on lipid or glycemia. Liraglutide or semaglutide therapy had discontinuation rates of 2.4%-11.4% which overlapped with 0.7%-8.6% in control groups. The frequency of adverse events was comparable between the treatment groups and the control groups (66.5%-95.8% vs 46.9%-96.1%), which were mild to moderate graded by studies.

Conclusion

Liraglutide and semaglutide therapy led to a clinically relevant (⩾5%) weight loss of 48.2%-88.7% among obese/overweight adults without diabetes. Both liraglutide and semaglutide are associated with weight loss and are well-tolerated.

SUBMITTER: Deng Y

PROVIDER: S-EPMC9260566 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:ImportancePhase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management.ObjectiveTo compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.0 mg (both with diet and physical activity), in people with overweight or obesity.Design, setting, and participantsRandomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).InterventionsParticipants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity. Participants unable to tolerate 2.4 mg of semaglutide could receive 1.7 mg; participants unable to tolerate 3.0 mg of liraglutide discontinued treatment and could restart the 4-week titration. Placebo groups were pooled (n = 85).Main outcomes and measuresThe primary end point was percentage change in body weight, and confirmatory secondary end points were achievement of 10% or more, 15% or more, and 20% or more weight loss, assessed for semaglutide vs liraglutide at week 68. Semaglutide vs liraglutide comparisons were open-label, with active treatment groups double-blinded against matched placebo groups. Comparisons of active treatments vs pooled placebo were supportive secondary end points.ResultsOf 338 randomized participants (mean [SD] age, 49 [13] years; 265 women [78.4%]; mean [SD] body weight, 104.5 [23.8] kg; mean [SD] body mass index, 37.5 [6.8]), 319 (94.4%) completed the trial, and 271 (80.2%) completed treatment. The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001); weight change with pooled placebo was -1.9%. Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide (70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}], 55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}], and 38.5% vs 6.0% [odds ratio, 8.2 {95% CI, 3.5 to 19.1}], respectively; all P < .001). Proportions of participants discontinuing treatment for any reason were 13.5% with semaglutide and 27.6% with liraglutide. Gastrointestinal adverse events were reported by 84.1% with semaglutide and 82.7% with liraglutide.Conclusions and relevanceAmong adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, added to counseling for diet and physical activity, resulted in significantly greater weight loss at 68 weeks.Trial registrationClinicalTrials.gov Identifier: NCT04074161.

Project description:BackgroundNowadays, diabetes mellitus is a serious public health problem in Ethiopia that has a profound impact on the health care system. However, no systematic synthesis and meta-analysis has been performed to depict the national prevalence. Hence, we authors aimed to assess the pooled prevalence of diabetes mellitus and its association with central obesity, overweight/obesity among adults in Ethiopia.MethodsWe did a systematic review and meta-analysis of 15 eligible studies on the national prevalence of DM and its association with central obesity, and overweight/obesity among adults in Ethiopia. We searched PubMed/Medline, Science Direct, Embase, and Google Scholar, from August 01 up to October 28, 2021, in accordance with PRISMA guidelines. Joanna Briggs Institute (JBI) critical appraisal tool was used to assess the quality of studies. Analysis was done using STATA version 14 software. Heterogeneity was checked using the I-squared test, and the publication bias was examined by funnel plot and eggers test. Moreover, Sensitivity analysis was done to check the influence of small studies on the outcome. The trim and fill analysis was performed to estimate the potentially missing articles because of publication bias.ResultTotal of 15 studies that met the inclusion criteria were included and the pooled prevalence of diabetes mellitus of the Federal Democratic Republic of Ethiopia was 6.26 (95%CI: 4.74-7.78). In the subgroup analysis, the prevalence of diabetes mellitus among the studies conducted in 2017 and before was 4.56 (95%CI: 2.98-6.14) but in studies done after 2017 was 7.55(95%CI: 4.69-10.41). The burden of diabetes mellitus was 5.79 times higher among those adults who had central obesity (OR = 5.79; 95%CI; 3.14-10.70), 5.70 times higher among adults who had overweight/obesity (OR = 5.70, 95%CI: 3.35-9.70).ConclusionThe national prevalence of diabetes mellitus among adults in Ethiopia was higher and associated with central obesity, and overweight/obesity. Hence, the government of Ethiopia and stakeholders should give attention to strengthen the current health system regarding non-communicable diseases like diabetes mellitus and obesity/overweight.